We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 1,169

5 Measures International Auto Companies Can Take to Avoid Being Named in an ITC Complaint
  • Foley & Lardner LLP
  • USA
  • May 4 2017

The Automotive Industry is international. That’s no secret. It crosses continents in its industry shows and its proud place in furious pop-culture


Section 337 and the New Trump Administration: Your Top Ten Questions Answered
  • Foley & Lardner LLP
  • USA
  • May 3 2017

As shown by the recent announcement by the Trump Administration of a Section 232(b) national security review of steel imports, (a type of


How Will The Supreme Court Choreograph The Biosimilar Patent Dance?
  • Foley & Lardner LLP
  • USA
  • May 2 2017

On April 26, 2017, the Supreme Court heard oral arguments in Amgen v. Sandoz, where the parties have asked the Court to interpret two of the


2017 Mid-Year Statistics Point to Continued Rise in IPR Petitions
  • Foley & Lardner LLP
  • USA
  • April 28 2017

March 31st marked the mid-point of the PTAB’s fiscal year and the release of mid-year statistics on AIA proceedings. The full report of the mid-year


No Nexus For Novartis Gilenya Patent
  • Foley & Lardner LLP
  • USA
  • April 25 2017

In Novartis AG v. Torrent Pharmaceuticals Ltd., the Federal Circuit affirmed the decision of the USPTO Patent Trial and Appeal Board (PTAB


Angiomax Patents Limited To Example
  • Foley & Lardner LLP
  • USA
  • April 18 2017

In The Medicines Co. v. Mylan, Inc., the Federal Circuit construed composition claims of two Angiomax patents as requiring the recited “batches” to


PTAB Not Bound By Prior Court Decisions Upholding Exelon Patents
  • Foley & Lardner LLP
  • USA
  • April 11 2017

In Novartis v. Noven Pharmaceuticals, Inc., the Federal Circuit affirmed the USPTO Patent Trial and Appeal Board (PTAB) decisions invalidating


Biosimilar Remedies Not Limited Without Full Patent Dance
  • Foley & Lardner LLP
  • USA
  • March 14 2017

The judge presiding over the pending biosimilar litigation between Janssen and CelltrionHospira has issued guidance regarding the ramifications of a


Will The Avastin Biosimilar Patent Dance Go On?
  • Foley & Lardner LLP
  • USA
  • March 7 2017

Judge Sleet of the U.S. District Court for the District of Delaware has dismissed Genentech’s complaint against Amgen for allegedly failing to comply


One is Not Enough - Infringement Liability under 271(f)(1)
  • Foley & Lardner LLP
  • USA
  • March 6 2017

In Life Technologies Corp. v. Promega Corp., Slip Op. 14-1538 (Feb. 22, 2017), the U.S. Supreme Court held that the supply of a single component of a